Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line

Danila Coradini, Cinzia Pellizzaro, Giuliana Miglierini, Maria Grazia Daidone, Alberto Perbellini

Research output: Contribution to journalArticle

Abstract

The potential clinical utility of sodium butyrate, a natural compound known to inhibit tumor-cell growth, is hampered by the difficulty of achieving effective in-vivo concentrations. The short half-life (about 5 minutes) of sodium butyrate results in rapid metabolism and excretion. To increase the availability of sodium butyrate over a longer period of time, we co-valently linked it to hyaluronic acid (a component of the extracellular matrix). Its major advantages as a drug carrier consist in its high biocompatibility and its ability to bind CD44, a specific membrane receptor frequently overexpressed on the tumor-cell surface. The degree of substitution of hyaluronic acid with butyrate residues ranged from d.s. = 0.10 to d.s. = 2.24 (1.8-28.4% w/w). The biological activity of hyaluronic- acid-butyric-ester derivatives was evaluated in terms of the inhibition of the growth of the MCF7 cell line and compared with that of sodium butyrate. After 6 days of treatment, we observed a progressive improvement of the anti- proliferative activity up to d.s. = 0.20; thereafter, the anti-proliferative effect of the ester derivatives decreased. Fluorescence microscopy showed that after 2 hr of treatment fluorescein-labelled compounds appeared to be almost completely internalized into MCF7 cells, expressing CD44 standard and variant isoforms. These findings indicate that hyaluronic acid could offer an important advantage in drug delivery, in addition to its biocompatibility: the ability to bind to CD44, which are known to be frequently over-expressed on the tumor-cell surface.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalInternational Journal of Cancer
Volume81
Issue number3
Publication statusPublished - 1999

Fingerprint

Butyric Acid
Hyaluronic Acid
Breast Neoplasms
Cell Line
MCF-7 Cells
Pharmaceutical Preparations
Esters
Neoplasms
Drug Carriers
Butyrates
Growth
Fluorescein
Fluorescence Microscopy
Extracellular Matrix
Half-Life
Protein Isoforms
Membranes
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hyaluronic acid as drug delivery for sodium butyrate : Improvement of the anti-proliferative activity on a breast-cancer cell line. / Coradini, Danila; Pellizzaro, Cinzia; Miglierini, Giuliana; Daidone, Maria Grazia; Perbellini, Alberto.

In: International Journal of Cancer, Vol. 81, No. 3, 1999, p. 411-416.

Research output: Contribution to journalArticle

Coradini, Danila ; Pellizzaro, Cinzia ; Miglierini, Giuliana ; Daidone, Maria Grazia ; Perbellini, Alberto. / Hyaluronic acid as drug delivery for sodium butyrate : Improvement of the anti-proliferative activity on a breast-cancer cell line. In: International Journal of Cancer. 1999 ; Vol. 81, No. 3. pp. 411-416.
@article{cc6d4896d20b43f189641231d4df983d,
title = "Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line",
abstract = "The potential clinical utility of sodium butyrate, a natural compound known to inhibit tumor-cell growth, is hampered by the difficulty of achieving effective in-vivo concentrations. The short half-life (about 5 minutes) of sodium butyrate results in rapid metabolism and excretion. To increase the availability of sodium butyrate over a longer period of time, we co-valently linked it to hyaluronic acid (a component of the extracellular matrix). Its major advantages as a drug carrier consist in its high biocompatibility and its ability to bind CD44, a specific membrane receptor frequently overexpressed on the tumor-cell surface. The degree of substitution of hyaluronic acid with butyrate residues ranged from d.s. = 0.10 to d.s. = 2.24 (1.8-28.4{\%} w/w). The biological activity of hyaluronic- acid-butyric-ester derivatives was evaluated in terms of the inhibition of the growth of the MCF7 cell line and compared with that of sodium butyrate. After 6 days of treatment, we observed a progressive improvement of the anti- proliferative activity up to d.s. = 0.20; thereafter, the anti-proliferative effect of the ester derivatives decreased. Fluorescence microscopy showed that after 2 hr of treatment fluorescein-labelled compounds appeared to be almost completely internalized into MCF7 cells, expressing CD44 standard and variant isoforms. These findings indicate that hyaluronic acid could offer an important advantage in drug delivery, in addition to its biocompatibility: the ability to bind to CD44, which are known to be frequently over-expressed on the tumor-cell surface.",
author = "Danila Coradini and Cinzia Pellizzaro and Giuliana Miglierini and Daidone, {Maria Grazia} and Alberto Perbellini",
year = "1999",
language = "English",
volume = "81",
pages = "411--416",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Hyaluronic acid as drug delivery for sodium butyrate

T2 - Improvement of the anti-proliferative activity on a breast-cancer cell line

AU - Coradini, Danila

AU - Pellizzaro, Cinzia

AU - Miglierini, Giuliana

AU - Daidone, Maria Grazia

AU - Perbellini, Alberto

PY - 1999

Y1 - 1999

N2 - The potential clinical utility of sodium butyrate, a natural compound known to inhibit tumor-cell growth, is hampered by the difficulty of achieving effective in-vivo concentrations. The short half-life (about 5 minutes) of sodium butyrate results in rapid metabolism and excretion. To increase the availability of sodium butyrate over a longer period of time, we co-valently linked it to hyaluronic acid (a component of the extracellular matrix). Its major advantages as a drug carrier consist in its high biocompatibility and its ability to bind CD44, a specific membrane receptor frequently overexpressed on the tumor-cell surface. The degree of substitution of hyaluronic acid with butyrate residues ranged from d.s. = 0.10 to d.s. = 2.24 (1.8-28.4% w/w). The biological activity of hyaluronic- acid-butyric-ester derivatives was evaluated in terms of the inhibition of the growth of the MCF7 cell line and compared with that of sodium butyrate. After 6 days of treatment, we observed a progressive improvement of the anti- proliferative activity up to d.s. = 0.20; thereafter, the anti-proliferative effect of the ester derivatives decreased. Fluorescence microscopy showed that after 2 hr of treatment fluorescein-labelled compounds appeared to be almost completely internalized into MCF7 cells, expressing CD44 standard and variant isoforms. These findings indicate that hyaluronic acid could offer an important advantage in drug delivery, in addition to its biocompatibility: the ability to bind to CD44, which are known to be frequently over-expressed on the tumor-cell surface.

AB - The potential clinical utility of sodium butyrate, a natural compound known to inhibit tumor-cell growth, is hampered by the difficulty of achieving effective in-vivo concentrations. The short half-life (about 5 minutes) of sodium butyrate results in rapid metabolism and excretion. To increase the availability of sodium butyrate over a longer period of time, we co-valently linked it to hyaluronic acid (a component of the extracellular matrix). Its major advantages as a drug carrier consist in its high biocompatibility and its ability to bind CD44, a specific membrane receptor frequently overexpressed on the tumor-cell surface. The degree of substitution of hyaluronic acid with butyrate residues ranged from d.s. = 0.10 to d.s. = 2.24 (1.8-28.4% w/w). The biological activity of hyaluronic- acid-butyric-ester derivatives was evaluated in terms of the inhibition of the growth of the MCF7 cell line and compared with that of sodium butyrate. After 6 days of treatment, we observed a progressive improvement of the anti- proliferative activity up to d.s. = 0.20; thereafter, the anti-proliferative effect of the ester derivatives decreased. Fluorescence microscopy showed that after 2 hr of treatment fluorescein-labelled compounds appeared to be almost completely internalized into MCF7 cells, expressing CD44 standard and variant isoforms. These findings indicate that hyaluronic acid could offer an important advantage in drug delivery, in addition to its biocompatibility: the ability to bind to CD44, which are known to be frequently over-expressed on the tumor-cell surface.

UR - http://www.scopus.com/inward/record.url?scp=0032937370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032937370&partnerID=8YFLogxK

M3 - Article

C2 - 10209956

AN - SCOPUS:0032937370

VL - 81

SP - 411

EP - 416

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -